Literature DB >> 28753055

The association of isoconazole-diflucortolone in the treatment of pediatric tinea corporis.

Stefano Veraldi1, Rossana Schianchi2, Paolo Pontini1, Alberto Gorani1.   

Abstract

BACKGROUND: Tinea corporis is a common mycotic infection in children. Staphylococcus aureus superinfections may be observed in atopic children with tinea corporis suffering from severe pruritus and consequent scratching.
OBJECTIVE: From 2006 to 2011, we observed 288 children with mycologically proven tinea corporis. In 39 of them (13.5%) tinea corporis was superinfected by S. aureus: all these children were affected by atopic dermatitis. We interpreted these bacterial superinfections as the clinical result of scratching due to pruritus.
METHODS: In 2012, we decided to treat all children with a single lesion of tinea corporis with a combination of 1% isoconazole nitrate and 0.1% diflucortolone valerate cream (one application/day for 5-7 days), followed by a treatment with isoconazole or clotrimazole or ciclopirox cream (two applications/day for two weeks).
RESULTS: From 2012 to 2014, we observed 108 children with tinea corporis confirmed by mycological examinations. Clinical and mycological recovery was observed in 93 of them (86.1%). Only four of these children (3.7%) developed S. aureus superinfections.
CONCLUSIONS: Our study in atopic children with tinea corporis superinfected by S. aureus confirms that a topical therapy with the association isoconazole-diflucortolone is useful and safe.

Entities:  

Keywords:  Atopic dermatitis; Staphylococcus aureus; children; diflucortolone valerate; isoconazole nitrate; tinea corporis

Mesh:

Substances:

Year:  2017        PMID: 28753055     DOI: 10.1080/09546634.2017.1360988

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  1 in total

Review 1.  Tinea corporis: an updated review.

Authors:  Alexander Kc Leung; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2020-07-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.